Atea Pharmaceuticals, Inc. — Fiscal 2021 Form 10-K Summary
Business context and reporting period
Atea is a clinical-stage biopharmaceutical company developing oral antiviral therapies for COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The filing covers the fiscal year ended December 31, 2021, with subsequent events through February 28, 2022.
- Lead programs were bemnifosbuvir for COVID-19 and HCV, AT-752 for dengue, and an early-stage RSV program.
- Bemnifosbuvir was being repositioned from COVID-19 monotherapy to a potential combination regimen, initially with a protease inhibitor.
- In December 2021, Atea licensed worldwide ruzasvir from Merck for development in combination with bemnifosbuvir for HCV.
Financial results and key metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Collaboration revenue | $351.4 million | $48.6 million | +$302.7 million |
| Research and development expense | $167.2 million | $38.0 million | +$129.2 million |
| General and administrative expense | $45.8 million | $21.6 million | +$24.1 million |
| Total operating expenses | $213.0 million | $59.7 million | +$153.3 million |
| Income (loss) from operations | $138.4 million | $(11.0) million | +$149.4 million |
| Net income (loss) | $121.2 million | $(10.9) million | +$132.1 million |
| Basic diluted earnings (loss) per share | $1.46 / $1.37 | $(0.51) / $(0.51) | Improved |
| Net cash used in operating activities | $(87.0) million | $296.7 million provided | $(383.7) million |
| Cash and cash equivalents at year-end | $764.4 million | $850.1 million | $(85.7) million |
Reported operating margin was approximately 39.4% and net margin approximately 34.5% in 2021, compared with negative margins in 2020. These margins were driven principally by recognition of Roche collaboration revenue and are not representative of product profitability.
- All reported revenue was collaboration revenue; Atea has generated no commercial product revenue.
- The $351.4 million of 2021 collaboration revenue included recognition of all remaining deferred revenue after Roche gave notice of termination of the Roche License Agreement.
- R&D expense included $93.5 million of external COVID-19 costs, $27.5 million of HCV costs, $9.4 million of dengue costs, $1.9 million of RSV costs and $34.9 million of internal R&D costs.
- R&D expense included a $25.0 million charge for the ruzasvir license upfront payment.
- Stock-based compensation was $39.6 million in 2021, compared with $7.5 million in 2020.
- The company disclosed no debt balances or debt financing arrangements. Liquidity consisted primarily of cash and money market funds.
- At December 31, 2021, total assets were $772.9 million, total liabilities were $62.8 million and stockholders’ equity was $710.1 million.
Material changes versus the prior comparable period
- Revenue increased sharply because the Roche termination notice resulted in recognition of the remaining deferred revenue. This was a nonrecurring accounting event rather than product sales.
- Operating cash flow shifted from $296.7 million of cash provided in 2020 to $87.0 million used in 2021, primarily because deferred revenue decreased by $301.4 million after recognition.
- R&D spending increased more than fourfold as Atea advanced COVID-19, HCV and dengue programs and expanded personnel and external development activities.
- Roche terminated its license agreement worldwide, effective February 10, 2022. Atea regained worldwide rights but also became responsible for the full future development costs of bemnifosbuvir and certain transition expenses.
- The Phase 2 MOONSONG outpatient COVID-19 trial did not meet its primary endpoint in the overall population. The hospitalized Phase 2 trial was closed out, and the Phase 3 MORNINGSKY and MEADOWSPRING trials were discontinued or closed out without sufficient enrollment for meaningful statistical analyses.
- Atea entered into a sales agreement allowing issuance of up to $200.0 million of common stock; no shares had been issued under the agreement as of December 31, 2021.
Guidance, outlook, risks and unusual items
- Management stated that cash and cash equivalents at December 31, 2021 were expected to fund planned operations through at least 2025, although this estimate depends on assumptions that may prove incorrect.
- The company expects significant operating losses and increased cash use in 2022 and for the foreseeable future because it has no approved products and expects no near-term product revenue.
- Planned activities included developing a bemnifosbuvir/protease-inhibitor COVID-19 combination, initiating a Phase 2 bemnifosbuvir/ruzasvir HCV study, advancing AT-752 into dengue challenge and Phase 2 studies, and nominating an RSV lead candidate and beginning IND-enabling work.
- The company had not yet developed or acquired a protease inhibitor for the proposed COVID-19 combination, making the program dependent on early discovery, licensing or acquisition efforts.
- Under the Merck agreement, Atea paid or accrued a $25.0 million nonrefundable ruzasvir upfront payment and may owe up to $135.0 million in development and regulatory milestones, up to $300.0 million in sales milestones, and tiered royalties ranging from high single digits to mid-teens percentages.
- Key risks include clinical failure, uncertain regulatory approval, rapid changes in the COVID-19 treatment landscape, competition from approved therapies, manufacturing dependence on third parties, supply concentration, intellectual-property challenges and the need for additional financing.
- Management and KPMG reported effective disclosure controls and internal control over financial reporting as of December 31, 2021. The financial statement and internal-control audits received unqualified opinions.
Most important facts for an investor to verify
- Separate recurring operating performance from the $351.4 million of Roche-related collaboration revenue recognized in 2021.
- Confirm current cash burn, remaining cash runway and the cost implications of Atea assuming full responsibility for bemnifosbuvir development after Roche’s termination.
- Track whether Atea identifies a viable protease inhibitor and initiates a clinical COVID-19 combination program.
- Review results and enrollment for the planned bemnifosbuvir/ruzasvir HCV program and AT-752 dengue studies.
- Assess the financial impact of the Merck milestone and royalty obligations and the availability of ruzasvir clinical supply.
- Monitor potential equity issuance under the $200 million sales agreement and resulting dilution.
- Evaluate whether clinical and regulatory data support the company’s claims regarding efficacy, safety, resistance barriers and commercial differentiation.